FY2023: revenue growth, operating profit growth and net profit decline
First written in FY2023. . Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026FY2026: revenue growth, operating profit decline and net profit growth disclosedAnnual report
「For the consolidated fiscal year, the Group reported net sales of ¥3,104,064 million, up 4.8% year on year, operating income of ¥36,164 million, down 5.0%, and ordinary income of ¥38,634 million, down 4.6%. In addition, due mainly to recording a gain on sales of investment securities of ¥25,331 million as extraordinary income from reducing cross-shareholdings, net income attributable to owners of the parent was ¥41,746 million, up 52.4%.」
In FY2026, revenue increased while operating profit and ordinary profit declined. Net income attributable to owners of the parent increased substantially due to gains on sales, including gains from the reduction of cross-shareholdings. - FY2024FY2024: revenue and profit growth disclosedAnnual report
「For the current consolidated fiscal year, the Group reported net sales of ¥2,858.5 billion (up 6.0% year on year), operating profit of ¥38.460 billion (up 27.6%), ordinary profit of ¥39.997 billion (up 21.8%), and net profit attributable to owners of the parent of ¥29.558 billion (up 14.6%).」
In FY2024, revenue, operating profit, ordinary profit and net income attributable to owners of the parent all increased year on year. - FY2023First statedAnnual report
「The Group's results for the consolidated fiscal year were as follows. Revenue rose 4.3% year on year to ¥2,696.069 billion, mainly due to a substantial increase in revenue from the wholesale business for prescription pharmaceuticals and other products. Gross profit increased by ¥4.617 billion year on year due to the effect of higher revenue and the maintenance of the gross profit margin. As a result, operating profit rose 3.6% to ¥30.148 billion and ordinary profit rose 0.8% to ¥32.831 billion. Net income attributable to owners of the parent declined 19.9% to ¥25.786 billion, mainly due to the recording of ¥9.303 billion in gains on sales of investment securities as extraordinary income, ¥1.159 billion in impairment losses on investment securities and ¥993 million in provision for antitrust-related loss reserves as extraordinary losses.」
In FY2023, revenue, operating profit and ordinary profit increased, while net income attributable to owners of the parent declined due to impairment losses on investment securities and antitrust-related loss reserves.